Parallel Advisors’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
– Sell
-135
Closed -$612 – 3613
2025
Q1
$612 Sell
135
-96
-42% -$508 ﹤0.01% 3210
2024
Q4
$1.63K Hold
231
– – ﹤0.01% 3021
2024
Q3
$1.88K Hold
231
– – ﹤0.01% 2909
2024
Q2
$1.48K Buy
+231
New +$1.48K ﹤0.01% 2879
2023
Q4
– Sell
-452
Closed -$4.57K – 3385
2023
Q3
$4.57K Sell
452
-14
-3% -$167 ﹤0.01% 2531
2023
Q2
$5.83K Sell
466
-74
-14% -$881 ﹤0.01% 2378
2023
Q1
$6.3K Buy
540
+30
+6% +$382 ﹤0.01% 2328
2022
Q4
$5.42K Buy
510
+256
+101% +$2.47K ﹤0.01% 2298
2022
Q3
$2K Buy
254
+57
+29% +$755 ﹤0.01% 2659
2022
Q2
$3K Buy
+197
New +$3.36K ﹤0.01% 2450
2022
Q1
– Sell
-72
Closed -$3K – 3084
2021
Q4
$3K Sell
72
-34
-32% -$1.55K ﹤0.01% 2577
2021
Q3
$5K Buy
+106
New +$5.78K ﹤0.01% 2349

Other funds holding HCAT

Parallel Advisors's HCAT Position: Q2 2025 in Review

Parallel Advisors sold out of Health Catalyst (HCAT) in Q2 2025, closing a stake of 135 shares — an estimated $612 sold.

Parallel Advisors first reported a position in HCAT in Q3 2021 and held it in 12 quarters. The position peaked at $6.3K in Q1 2023. 145 funds tracked by Wall St. Rank hold HCAT as of Q2 2025.

  • Parallel Advisors reported no remaining Health Catalyst position as of Q2 2025 after selling out during the quarter.
  • Parallel Advisors sold 135 Health Catalyst shares in Q2 2025, an estimated $612.
  • Parallel Advisors first reported a position in Health Catalyst in Q3 2021 and held it in 12 quarters.
  • Parallel Advisors's Health Catalyst position peaked at $6.3K in Q1 2023.
  • 145 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2025.

Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.